Clinical Trials Logo

Clinical Trial Summary

Preeclampsia is a serious condition that can occur during pregnancy and can pose problems for both the mother and the baby. It occurs in approximately 2-8% of all pregnancies globally and is caused by issues with blood vessels, leading to elevated blood pressure and other related health concerns. Additionally, insufficient nutrition and inflammation within the mother's body may contribute to the development of preeclampsia. The HALP score serves as a tool to assess various elements within the blood, indicating inflammation or inadequate nutrition. Although it has been utilized in other medical contexts, its application during pregnancy remains limited. The HALP score has been employed to predict the emergence of ailments such as heart disease and cancer. Given that preeclampsia can stem from inflammation and poor nutrition, the potential of the HALP score in predicting the likelihood of preeclampsia during pregnancy is being examined through research.


Clinical Trial Description

Preeclampsia is a hypertensive disorder affecting multiple body systems that poses a risk of maternal and fetal morbidity and mortality. The global prevalence of preeclampsia is estimated to be around 2-8% of all pregnancies. The pathophysiology of preeclampsia is complex and involves endothelial dysfunction and vasospasm, resulting in hypertension and end-organ damage. The development of preeclampsia is influenced by various factors, including abnormalities in the placenta, genetic factors, and maternal immune system. In addition, poor maternal nutrition and inflammation have also been identified as potential contributors to the development of preeclampsia. The HALP score is a composite measure of hemoglobin, albumin, lymphocyte, and platelet parameters that has been suggested as a possible indicator of systemic inflammation and malnutrition. Although the HALP score has not been extensively studied in obstetrics, it has been investigated in various medical fields as a predictor of adverse outcomes such as cardiovascular disease and cancer. Given the significance of inflammation and malnutrition in the development of preeclampsia, it is important to investigate the potential usefulness of the HALP score in predicting this condition. Due to the limited research on the application of the HALP score in obstetrics and the possible role of inflammation and malnutrition in the pathogenesis of preeclampsia, a retrospective study is being planned to explore the potential utility of the HALP score as a predictor of preeclampsia. By analyzing the relationship between the HALP score and the development of preeclampsia, valuable insights can be obtained regarding the potential involvement of inflammation and malnutrition in the development of this disorder. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05816044
Study type Observational
Source Prof. Dr. Cemil Tascioglu Education and Research Hospital Organization
Contact
Status Completed
Phase
Start date February 22, 2023
Completion date July 15, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT03299777 - Correlation Between Changes in Liver Stiffness and Preeclampsia as Shown by Fibroscan N/A
Completed NCT03650790 - C1q/TNF-related Protein 9 (CTRP 9) Level in Preeclamptic Obese and Non-obese Pregnancies N/A
Recruiting NCT03605511 - TTP and aHUS in Complicated Pregnancies
Not yet recruiting NCT03302260 - Identifying Methods for Postpartum Reduction of Vascular Events: Pilot Randomized Controlled Trial N/A
Completed NCT02911701 - Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features Phase 4
Completed NCT01911494 - Community Level Interventions for Pre-eclampsia N/A
Terminated NCT02025426 - Phenylephrine Versus Ephedrine in Pre-eclampsia Phase 4
Completed NCT01352234 - Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia Phase 4
Active, not recruiting NCT02031393 - Establishing First Trimester Markers for the Identification of High Risk Twin N/A
Terminated NCT00141310 - Sildenafil Citrate for the Treatment of Established Pre-Eclampsia Phase 2
Completed NCT00157521 - L-Arginine in Pre-Eclampsia Phase 3
Completed NCT04795154 - Prenatal Yoga as Complementary Therapy of Preeclampsia N/A
Completed NCT00004399 - Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia N/A
Completed NCT00005207 - Renin and Prorenin in Pregnancy N/A
Recruiting NCT04551807 - Natural Versus Programmed Frozen Embryo Transfer (NatPro) Phase 3
Terminated NCT04092829 - Impact of Corpus Luteum Presence or Absence in the Incidence of Preeclampsia After Frozen Embryo Transfer N/A
Recruiting NCT06067906 - Weight Loss Following an Episode of Pre-eclampsia Using a Dissociated or Hypocaloric Diet in Overweight or Obese Patients N/A
Recruiting NCT06317467 - Role of Anti-C1q Autoantibodies in Pregnancy
Completed NCT02218931 - ESTEEM - Effect of Simple, Targeted Diet in Pregnant Women With Metabolic Risk Factors on Pregnancy Outcomes N/A
Active, not recruiting NCT04484766 - Preeclampsia Associated Vascular Aging